Case Summary - Joy Bryant

[Federal Register: June 25, 2007 (Volume 72, Number 121)]
[Notices]
[Page 34689]
From the Federal Register Online via GPO Access
[waids.access.gpo.gov] [DOCID:fr25jn07-69]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Findings of Scientific Misconduct

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assi
tional action in the following case:

Joy Bryant, University of Oklahoma Health Sciences Center: Based on the report of an invi
of Oklahoma Health Sciences Center (OUHSC) and additional analysis conducted by the C
 oversight review, the U.S. Public Health Service (PHS) found that Ms. Joy Bryant, Tribal Ef
phlebotomist, OUHSC, engaged in scientific misconduct in research supported by National
Sciences (NIEHS), National Institutes of Health (NIH), grant R01 ES008755.

Specifically, Ms. Bryant falsified research in the TEAL study by substituting or conspiring w
her blood or blood of another phlebotomist for blood samples of 10-15 child participants in

Ms. Bryant has entered into a Voluntary Exclusion Agreement (Agreement) in which she h
three (3) years, beginning on May 30, 2007:

(1) To exclude herself from any contracting or subcontracting with any agency of the Unit
or involvement in nonprocurement programs of the United States Government as defined in
Guidelines to Agencies on Governmentwide Debarment and Suspension at 2 CFR part 375.

(2) To exclude herself from serving in any advisory capacity to PHS, including but not limi
committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative Oversight
Office of Research Integrity
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852
(240) 453-8800

John Dahlgren
Acting Director
Office of Research Integrity

http://ori.dhhs.gov/misconduct/cases/Bryant.shtml

8/30/2007
New CGS publication identifies best practices in RCR.
Case Summary - James David Lieber

[Federal Register: July 23, 2007 (Volume 72, Number 140)]

[Notices]
[Page 40157]
From the Federal Register Online via GPO Access
[wais.access.gpo.gov] [DOCID:fr23y07-55]

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Findings of Research Misconduct

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assi
dinal action in the following case:

James David Lieber, University of California at Los Angeles: Based on the findings of an in
California at Los Angeles (UCLA) and additional analysis and information obtained by the (C
its oversight review, the U.S. Public Health Service (PHS) found that James David Lieber, t
stitute for Neuroscience and Human Behavior, Integrated Substance Abuse Programs, U
research funded by National Institute on Drug Abuse (NIDA), National Institutes of Health

Mr. Lieber knowingly and intentionally falsified and fabricated multiple follow-up interviews,
records of human subject study participants and entered such false and fabricated data into
follow-up interviews of opiate users were planned to be completed as part of a study of ger
users in California. Mr. Lieber was assigned to interview 53 of the 132 subjects located for
period, Mr. Lieber falsely claimed to have conducted face-to-face interviews for the study w
subjects revealed that they had not been interviewed for the study. A review by the institut
fabricated interviews for 20 of the 53 interviews assigned to him. In addition, he falsified th
and caused the entry of false information into the study tracking and locating data base for
cluded the theft of $5180 for incentive payments to subjects and travel expenses.

ORI has implemented the following administrative actions for a period of three (3) years, b
(1) Mr. Lieber is debarred from eligibility for any contracting or subcontracting with any age
and from eligibility or involvement in nonprocurement programs of the United States Gover
transactions" as defined in HHS' implementation of OMB Guidelines to Agencies on Gover
at 2 CFR part 376, et seq.; and

(2) Mr. Lieber is prohibited from serving in any advisory capacity to PHS, including but not l
committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative Oversight

http://ori.dhhs.gov/misconduct/cases/Lieber.shtml

8/30/2007
New CGS publication identifies best practices in RCR